Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 30,654 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total transaction of $7,379,643.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69.
Beigene Stock Performance
ONC opened at $255.37 on Friday. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $260.98. The stock has a market capitalization of $24.99 billion, a P/E ratio of -30.99, a price-to-earnings-growth ratio of 9.44 and a beta of 0.63. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.
About Beigene
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Further Reading
- Five stocks we like better than Beigene
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Are Earnings Reports?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- Insider Selling Explained: Can it Inform Your Investing Choices?
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
